Terms: = Thyroid cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
70 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
3. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
4. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary thyroid Carcinoma: A Pitfall in thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
5.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
6. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
7. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract] [Full Text] [Related]
8. Papillary thyroid carcinoma with desmoid-type fibromatosis: the clinicopathological features with characteristic imaging and molecular correlation requiring comprehensive treatment.
Huang H; Li L; Liu X; Zhao L; Cui Z; Zhang R; Chen S
Hum Pathol; 2023 Jun; 136():84-95. PubMed ID: 37019411
[TBL] [Abstract] [Full Text] [Related]
9. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Application of Next-Generation Sequencing in Advanced thyroid cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
11. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric thyroid cancers.
Franco AT; Ricarte-Filho JC; Isaza A; Jones Z; Jain N; Mostoufi-Moab S; Surrey L; Laetsch TW; Li MM; DeHart JC; Reichenberger E; Taylor D; Kazahaya K; Adzick NS; Bauer AJ
J Clin Oncol; 2022 Apr; 40(10):1081-1090. PubMed ID: 35015563
[TBL] [Abstract] [Full Text] [Related]
12. cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Aleksakhina SN; Imyanitov EN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681592
[TBL] [Abstract] [Full Text] [Related]
13. Total thyroidectomy can still remain the method of choice in some Bethesda III cases.
Lukas J; Hintnausova B; Sykorova V; Syrucek M; Maly M; Duskova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):61-68. PubMed ID: 34282807
[TBL] [Abstract] [Full Text] [Related]
14. Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility.
Mio C; Verrienti A; Pecce V; Sponziello M; Damante G
Endocrine; 2021 Sep; 73(3):648-657. PubMed ID: 33821390
[TBL] [Abstract] [Full Text] [Related]
15. Histology-based molecular profiling improves mutation detection for advanced thyroid cancer.
Eszlinger M; Khalil M; Gillmor AH; Huang H; Stewardson P; McIntyre JB; Morrissy S; Paschke R
Genes Chromosomes Cancer; 2021 Aug; 60(8):531-545. PubMed ID: 33749950
[TBL] [Abstract] [Full Text] [Related]
16. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract] [Full Text] [Related]
17. Clinical Utility of BRAF, nras, and TERT Promoter Mutation in Preoperative thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais cancer Hospital.
Perdana AB; Putri RI; Rachmawati R; Andinata B; Brahma B
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3267-3277. PubMed ID: 33247684
[TBL] [Abstract] [Full Text] [Related]
18. The Integrated Analyses of Driver Genes Identify Key Biomarkers in thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
19. Malignant struma ovarii: next-generation sequencing of six cases revealed nras, Braf, and Jak3 mutations.
Poli R; Scatolini M; Grosso E; Maletta F; Gallo M; Liscia D; Nelva A; Cesario F; Forte G; Metovic J; Volante M; Arvat E; Papotti M
Endocrine; 2021 Jan; 71(1):216-224. PubMed ID: 32743766
[TBL] [Abstract] [Full Text] [Related]
20. Amplicon-Based NGS Panels for Actionable cancer Target Identification in Follicular Cell-Derived thyroid Neoplasia.
Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
[TBL] [Abstract] [Full Text] [Related]
[Next]
